Evaluating Xilonox in Symptomatic Colo-Rectal Cancer
Research type
Research Study
Full title
A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy
IRAS ID
154612
Contact name
Tamas Hickish
Contact email
Sponsor organisation
XBiotech Germany GmbH
Eudract number
2014-000550-12
ISRCTN Number
n/a
Clinicaltrials.gov Identifier
n/a
Research summary
The purpose of this study is to look at how well the drug XILONIX can increase muscle mass and help with tiredness in patients with metastatic colorectal cancer. XILONIX contains an antibody (a protein that binds to a substance related to the disease). By binding to this substance, XILONIX may help block tumour-related inflammation that can result in tumour growth, muscle loss, and fatigue.
In a previous study using XILONIX, several patients with metastatic colorectal cancer gained muscle mass and some showed stabilization of their tumours. Those patients who gained muscle mass also had a longer survival than those who did not. We hope the information learned from this study will help doctors learn more about the use of XILONIX in patients with advanced colorectal cancer.
REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
14/LO/0866
Date of REC Opinion
14 Jul 2014
REC opinion
Further Information Favourable Opinion